drugset / Trial / NCT01475461
Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes
RandomizedParallel-groupTriple-blindTreatment
Summary
B1621007 is designed to study the safety and efficacy of PF-04937319 in patients with type 2 diabetes
Timeline
- Start
- 2011-11
- Primary completion
- 2013-01
- Completion
- 2013-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NERIGLIATIN | Small molecule | 3 mg | Oral |
| Subject | NERIGLIATIN | Small molecule | 20 mg | Oral |
| Subject | NERIGLIATIN | Small molecule | 50 mg | Oral |
| Subject | NERIGLIATIN | Small molecule | 100 mg | Oral |
| Comparator | Sitagliptin | Small molecule | 100 mg | Oral |